Preventing Phase III Failures

Publication
Article
BioPharm InternationalBioPharm International-06-15-2016
Volume 2016 ebook
Issue 1
Pages: 35–38

Adopting best practices and collaborating more closely with contract research organizations can help drugs get past Phase III.

Only half of new drugs make it past Phase III. Adopting best practices and collaborating more closely with contract research organizations can help ensure success.

Download the

BioPharm International 2016 Outsourcing Resources eBook

.

 

 

 

 

 

 

 

Articles in this issue
BPsupp0616_RT_manufacturing_185.jpg
Contract Service Providers Gear Up to Develop Emerging Therapies
BPsupp0616_RT_business_185.jpg
Biopharma Service Providers Address a Full Plate of Challenges
BPsupp0616_SupplyChain_Vetter_185.jpg
Dealing with Pharmaceutical Supply-Chain Complexities
BPsupp0616_3MDrugDelivery_185.jpg
Keeping it Simple: Collaborating for Success in Drug Delivery
BPsupp0616_china_185.jpg
Regulatory Reform in China: Implications for Global Biopharmaceutical Companies
BPsupp0616_Langer_185.jpg
Biomanufacturers Demand Higher Quality Standards in 2016
BPsupp0616_Parexel_185.jpg
Preventing Phase III Failures
BPsupp0616_CMO-News_185.jpg
Outsourcing Industry Marked by Considerable Investments in 2016
Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Christa Myers, CRB Group; Nadiyra Walker Speight, Fujifilm Diosynth Biotechnologies
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Fujifilm Completes Expansion of Cell Therapy Facility

Nicholas Saraceno
November 22nd 2024
Article

The company officially launched new production suites, a revamp of its development labs, and more at its Thousand Oaks, Calif., cell therapy manufacturing facility.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

BioPharmaSpec Launches Three New R&D Facilities in Europe

Feliza Mirasol
November 20th 2024
Article

The new European facilities located in German, Italy, and Lithuania will specialize in drug discovery and R&D services.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

SEKISUI Completes CDMO Capacity Expansion for CGMP Biopharma Manufacturing

Feliza Mirasol
November 19th 2024
Article

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Thermo Fisher Introduces New CDMO and CRO Services at CPHI Milan 2024

Patrick Lavery
October 10th 2024
Article

Thermo Fisher Scientific's launch of its Accelerator Drug Development follows expansions of sites in Cincinnati, Ohio, and Bend, Ore., earlier in 2024 to enable R&D, manufacturing, and testing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CPHI Annual Survey Suggests 54% of Biologics Capacity in 2028 to be Held by CMOs and Hybrid Companies

Feliza Mirasol
October 9th 2024
Article

The annual survey predicts that four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which will control 45% of all CMO capacity in Asia.

© 2024 MJH Life Sciences

All rights reserved.